Chang, Xiao L.
Webb, Gabriela M.
Wu, Helen L. http://orcid.org/0000-0001-7101-5160
Greene, Justin M.
Abdulhaqq, Shaheed
Bateman, Katherine B.
Reed, Jason S.
Pessoa, Cleiton
Weber, Whitney C. http://orcid.org/0000-0002-5868-8085
Maier, Nicholas
Chew, Glen M.
Gilbride, Roxanne M.
Gao, Lina
Agnor, Rebecca
Giobbi, Travis
Torgerson, Jeffrey
Siess, Don
Burnett, Nicole
Fischer, Miranda
Shiel, Oriene
Moats, Cassandra
Patterson, Bruce
Dhody, Kush
Kelly, Scott
Pourhassan, Nader
Magnani, Diogo M. http://orcid.org/0000-0002-1773-2406
Smedley, Jeremy http://orcid.org/0000-0003-3369-4662
Bimber, Benjamin N.
Haigwood, Nancy L.
Hansen, Scott G.
Brown, Timothy R.
Ndhlovu, Lishomwa C. http://orcid.org/0000-0001-5427-4187
Sacha, Jonah B. http://orcid.org/0000-0002-7633-3122
Article History
Received: 26 March 2021
Accepted: 11 May 2021
First Online: 7 June 2021
Competing interests
: J.B.S. and L.C.N. have received compensation for serving on the scientific advisory board of CytoDyn, a company that may have commercial interests in the results of this research. J.B.S. has also received compensation for consulting for CytoDyn. The potential conflict of interest has been reviewed and managed by the Oregon Health & Science University. L.C.N. is an advisor for Abbvie and ViiV. N.P. and S.K. are employees of CytoDyn, owner, and developer of Leronlimab. B.P. is an employee of IncellDX, a company providing Leronlimab-based CCR5 diagnostics. K.D. is an employee of Amarex Clinical Research, a company that manages clinical trials and regulatory matters for CytoDyn.